SEARCH

SEARCH BY CITATION

References

  • Brown M, Marmor M, Vaegan et al. (2006): ISCEV Standard for Clinical Electro-oculography (EOG) 2006. Doc Ophthalmol 113: 205212.
  • Ferrara N (2004): Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581611.
  • Ferrara N, Hillan KJ, Gerber HP & Novotny W (2004): Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391400.
  • Ferris FL III, Fine SL & Hyman L (1984): Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 16401642.
  • Friedman DS, O'Colmain BJ & Muñoz B (2004): Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564572.
  • Hood DC & Birch DG (1996): Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. J Opt Soc Am A Opt Image Sci Vis 13: 623633.
  • Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS & Recchia FM (2008): Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 115: 18371846.
  • Kvanta A, Algvere PV, Berglin L & Seregard S (1996): Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 19291934.
  • Ladewig M, Kraus H, Foerster MH & Kellner U (2003): Cone dysfunction in patients with late-onset cone dystrophy and age-related macular degeneration. Arch Ophthalmol 121: 15571561.
  • Lopez PF, Slippy BD, Lambert HM, Thach AB & Hinton DR (1996): Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37: 855868.
  • Maturi RK, Bleau LA & Wilson DL (2006): Electrophysiologic findings after. intravitreal bevacizumab (Avastin) treatment. Retina 26: 270274.
  • Meyerhardt JA & Mayer RJ (2005): Systemic therapy for colorectal cancer. N Engl J Med. 352: 476487.
  • Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB & Narayana KM (2007): Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143: 601606.
  • RegilloCD (ed.) (2010): American Academy of Ophthalmology:2008–2009, Basic and Clinical Science Course. Section 12: Retina and Vitreous 31–42.
  • Rich RM, Rosenfeld PJ & Puliafito CA (2006): Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495511.
  • Robinson CJ & Stringer SE (2001): The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853865.
  • Robson JG & Frishman LJ (1996): Photoreceptor and bipolar cell contributions to the cat electroretinogram: a kinetic model for the early part of the flash response. J Opt Soc Am A Opt Image Sci Vis 13: 613622.
  • Ronan S, Nusinowitz S, Swaroop A & Heckenlively JR (2006): Senile panretinal cone dysfunction in age-related macular degeneration (AMD): a report of 52 AMD patients compared to age-matched controls. Trans Am Ophthalmol Soc 104: 232240.
  • Sieving PA, Murayama K & Naarendorp F (1994): Push-pull model of the primate photopic electroretinogram: a role for hyperpolarizing neurons in shaping the b-wave. Vis Neurosci 11: 519532.
  • Walter P, Widder RA, Lüke C, Königsfeld P & Brunner R (1999): Electrophysiological abnormalities in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 237: 962968.
  • Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E & Bartz-Schmidt KU (2008): Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 28: 101109.